At last check, in the current trading session, Aerpio Pharmaceuticals Inc. (ARPO) stock had surged by 48.70% to $1.72. ARPO stock previously closed the session at $1.16. The stock volume traded 96.55 million shares. In the past year, up-to-date ARPO shares surged by 59.45% and in the past week, they moved up by 10.48%. In the past three and six months, the stock has shed -42.86% and -14.07%. Furthermore, Aerpio Pharmaceuticals is currently valued at $50.60 million and has 47.17 million outstanding shares.
What you need to know about Aerpio Pharmaceuticals
Aerpio Pharmaceuticals, Inc., a biopharmaceutical company that specifically focuses on the development and marketing of products and treatments for unmet needs and diseases. The treatments include therapeutic and novel compounds for the treatment of ocular diseases and diabetic disorders. Aerpio Pharmaceuticals is headquartered in Cincinnati, Ohio.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Read More
ARPO’s lead candidates and product offerings
Razuprotafib is a small molecule and a Tie2 pathway activator. It is the company’s lead product candidate that has Phase IIb clinical trial for the treatment of diabetic retinopathy which has been completed.
Products other than the lead candidate include ARP-1536 which is in development for the treatment of diabetic vascular complications. ARP-1536 is a humanized monoclonal antibody that is in the preclinical development stage.
ARPO stock also produces a selective stabilizer of hypoxia-inducible factor-1 alpha, known as GB004. It is used for the treatment of inflammatory bowel disease and is currently in Phase 1b clinical trial
Furthermore, there are bispecific antibodies made by APRO stock for the treatment of wet age-related macular degeneration and DME through intravitreal injection.
Aerpio Pharmaceuticals, Inc. has collaborated with Quantum Leap Healthcare Collaborative for the evaluation of razuprotafib in the treatment of acute respiratory distress syndrome in adult patients with moderate to severe COVID-19.
Announcement of the merger agreement with Aadi Bioscience
Today, 17th May 2021, Aerpio has announced that it is being acquired by Aadi Bioscience through a definitive merger agreement. The joined public organization will zero in on propelling Aadi’s lead item up-and-comer, FYARROTM. Following the proposed merger, Aerpio will change its name to “Aadi Bioscience, Inc.” Upon shutting of the exchange, the joined organization will be driven by Aadi’s CEO, Neil Desai, and settled in Los Angeles, California.
Aerpio’s governing body persistently attempted an extensive vital survey and has inferred that the proposed exchange with Aadi is to the greatest advantage of ARPO stockholders and investors. Aerpio’s BOD accepts that Aadi’s late-stage advancement program may offer huge health advantage to PEComa patients and significant potential for patients with tumors holding TSC1 or TSC2 inactivating changes.
All together with famous institutional financial backers, ARPO stock will join forces with Aadi as it propels FYARRO and endeavors to open the capability of mTOR as a helpful objective.
On the side of the consolidation, Aerpio has gone into subscription agreements to bring $155 million up in a Private Investment in Public Equity (PIPE) financing led by Acuta Capital Partners and KVP Capital and including Avoro Capital Advisors.
Along with the money anticipated from the two organizations at closing, the net proceeds of the PIPE financing are relied upon to fund the organization into 2024, empowering expected endorsement and business dispatch in PEComa just as culmination of a registrational preliminary in tumors holding TSC1 or TSC2 inactivating adjustments.
